Basilea Pharmaceutica AG Share Price
Stocks
BSLN
CH0011432447
Biotechnology & Medical Research
OTC Markets Traded|
Real-time Estimate
Cboe Europe
05:03:03 10/11/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 71.65 CHF | -0.76% |
|
-1.78% | +31.08% |
| Market Cap | 90Cr 109.23Cr 97Cr 81Cr 154.31Cr 10TCr 158.14Cr 1.07TCr 427.77Cr 5.48TCr 409.99Cr 401.21Cr 17TCr | P/E 2026 * |
12.7x | P/E 2027 * | 15.3x |
|---|---|---|---|---|---|
| Enterprise Value | 73Cr 89Cr 79Cr 66Cr 125.54Cr 8.33TCr 128.66Cr 873.13Cr 348.01Cr 4.46TCr 333.54Cr 326.4Cr 14TCr | EV / Sales 2026 * |
2.48x | EV / Sales 2027 * | 2.36x |
| Free-Float |
91.78% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Swiss Exchange
| BSLN | Delayed | |
London S.E.
| 0QNA | Delayed | |
|
CBOE
| 0QNA | Real-time | |
|
OTC Markets
| BPMUF | Delayed | |
|
Tradegate
| PK5 | Real-time | |
|
Deutsche Boerse AG
| PK5 | Delayed | |
|
Xetra
| PK5 | Delayed | |
|
Börse Stuttgart
| PK5 | Delayed | |
|
Boerse Muenchen
| PK5 | Real-time |
Last Transcript: Basilea Pharmaceutica AG
| 1 day | -0.76% | ||
| 1 week | -1.78% | ||
| Current month | +1.27% | ||
| 1 month | +9.13% | ||
| 3 months | +37.62% | ||
| 6 months | +30.13% | ||
| Current year | +31.08% |
| 1 week | 69.2 |  | 74.5 |
| 1 month | 64.4 | | 75.8 |
| Current year | 47.8 | | 75.8 |
| 1 year | 45.4 | | 75.8 |
| 3 years | 32 | | 75.8 |
| 5 years | 29.55 | | 75.8 |
| 10 years | 29.28 | | 95.35 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 61 | 19/04/2018 |
Adesh Kaul
DFI | Director of Finance/CFO | 52 | 10/04/2019 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 62 | 01/05/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Thomas Werner
BRD | Director/Board Member | 70 | 29/11/2011 |
| Chairman | 71 | 09/04/2013 | |
Nicole Onetto
BRD | Director/Board Member | 73 | 27/04/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 29/05/26 | Sell | -400 | 0.0030% | |||
| 13/05/26 | Sell | -1,043 | 0.0078% | |||
| 04/05/26 | Sell | 400 | 0.0030% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.76% | -1.78% | +58.10% | +105.74% | 109.23Cr | |
| +2.24% | +8.40% | +58.47% | +69.00% | 6.82TCr | |
| +0.56% | +8.87% | +15.24% | +89.04% | 5.98TCr | |
| +0.58% | +1.87% | +24.42% | +98.57% | 5.61TCr | |
| +2.55% | +15.52% | +30.43% | +120.17% | 4.77TCr | |
| +2.58% | +7.89% | +32.49% | +45.30% | 4.6TCr | |
| +4.09% | +6.37% | +228.06% | +899.75% | 4.33TCr | |
| -0.47% | +9.38% | +27.53% | +52.40% | 3.57TCr | |
| +0.22% | -1.21% | +95.89% | +70.65% | 3.47TCr | |
| +1.48% | +6.21% | -38.80% | +395.73% | 2.55TCr | |
| Average | +1.04% | +7.03% | +53.18% | +194.63% | 4TCr | |
| Weighted average by Cap. | +1.43% | +7.82% | +53.77% | +183.83% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 29Cr 36Cr 32Cr 27Cr 51Cr 3.36TCr 52Cr 351.78Cr 140.21Cr 1.8TCr 134.38Cr 131.51Cr 5.66TCr | 28Cr 34Cr 31Cr 26Cr 49Cr 3.23TCr 50Cr 338.69Cr 134.99Cr 1.73TCr 129.38Cr 126.61Cr 5.45TCr |
| Net income | 6.87Cr 8.36Cr 7.47Cr 6.23Cr 12Cr 783.97Cr 12Cr 82Cr 33Cr 419.71Cr 31Cr 31Cr 1.32TCr | 6.44Cr 7.84Cr 7Cr 5.85Cr 11Cr 735Cr 11Cr 77Cr 31Cr 393.49Cr 29Cr 29Cr 1.24TCr |
| Net Debt | -17Cr -20Cr -18Cr -15Cr -29Cr -1.91TCr -29Cr -200.12Cr -80Cr -1.02TCr -76Cr -75Cr -3.22TCr | -23Cr -28Cr -25Cr -21Cr -40Cr -2.63TCr -41Cr -275.41Cr -109.77Cr -1.41TCr -105.21Cr -102.96Cr -4.43TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/26/10 | CHF 71.70 | -0.69% | 4,027 |
| 09/26/09 | CHF 72.20 | +1.69% | 28,128 |
| 06/26/06 | CHF 71.00 | -0.56% | 25,815 |
| 05/26/05 | CHF 71.40 | -3.12% | 43,929 |
| 04/26/04 | CHF 73.70 | +0.96% | 52,743 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- BSLN Stock
Select your edition
All financial news and data tailored to specific country editions
